Benchmark Reiterates Speculative Buy Rating for BIOLASE (NASDAQ:BIOL)

Benchmark restated their speculative buy rating on shares of BIOLASE (NASDAQ:BIOL) in a research note issued to investors on Wednesday morning, Benzinga reports. The brokerage currently has a $0.40 target price on the medical technology company’s stock.

Several other analysts also recently commented on the company. StockNews.com assumed coverage on BIOLASE in a research note on Wednesday, September 25th. They set a sell rating on the stock. Ascendiant Capital Markets dropped their price objective on BIOLASE from $3.50 to $2.00 and set a buy rating on the stock in a research report on Tuesday, September 3rd.

BIOLASE Price Performance

Shares of BIOLASE stock opened at $0.02 on Wednesday. BIOLASE has a 1 year low of $0.02 and a 1 year high of $1.94. The firm’s 50-day moving average is $0.06 and its 200 day moving average is $0.11. The stock has a market cap of $501,105.00, a price-to-earnings ratio of 0.00 and a beta of 0.67.

BIOLASE (NASDAQ:BIOL) last issued its earnings results on Thursday, August 8th. The medical technology company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $11.56 million during the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 41.65%.

Institutional Investors Weigh In On BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC grew its position in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the quarter. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 8.79% of the company’s stock.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.